Salah-Eddin Al-Batran

Good to see that the IKF supported PREVENT FLOT9/HIPEC study, a study that is very difficult to recruit, has gained speed in recruitment: Preventive HIPEC with FLOT versus FLOT alone for resectable diffuse type gastroesophageal cancer by Thorsten O. Götze and Pompiliu Piso

IKF is happy to announce that the ADVACE study has recruited its first patient. The IIT led by Prof. Arndt Vogel evaluates an innovative combination of Atezolizumab and Derazantinib for pts with bile duct cancer and FGFR fusions/rearmaments

ESMO 2021 Our data on gastric/GEJ cancer patients with MSI from DANTE trial show that path response (TRG1a/b) following FLOT+Atezo was at 80%, including 50% complete path response. This is the highest path response rate seen in this disease ever. #ESMO21 #oncology #gastriccancer

Nicht verpassen! Ein neuer Artikel von mir: IKF @ ESMO Congress 2021 linkedin.com/pulse/ikf-esmo… via @LinkedIn

Nicht verpassen! Ein neuer Artikel von mir: Frankrter Symposium 365 linkedin.com/pulse/frankrte… via @LinkedIn

@SawsanChebli Unfassbar! Das schlimme ist, dass eine Straßenbaufirma von öffentlichen Aufträgen lebt!!!